Innovent to take IL-23 psoriasis drug to Chinese regulators after phase 3 win

Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese regulators.

The anti-IL-23 monoclonal antibody, called picankibart, hit all primary and key secondary endpoints in the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks